Boston Biotech Firm Appeals Patent Dispute Over Paxlovid Against Pfizer

A Boston drug developer is appealing to the Federal Circuit after losing an infringement case against Pfizer. The dispute centers on Pfizer’s Paxlovid, a leading COVID-19 treatment. The company argues that a critical issue regarding a typo in a patent document should have been decided by a jury. This development comes as the parties continue to navigate complex patent litigation in the pharma industry. More on the specifics of the case can be read in detail in the report by Law360.